Physician profile
Rajinder Singh
NPI 1518007889
$3,421.38
in general payments reported to CMS, 2019-2025
20 companies · $641 in 2025
The $641 reported for 2025 was more than what 83% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $596 · 2020: $411 · 2021: $497 · 2022: $374 · 2023: $447 · 2024: $455 · 2025: $641.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,544.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,543.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $630.25 | 2019-2025 | Gallant, Aveir, Amplatzer Talisman |
| Medtronic, INC. | $519.69 | 2021-2025 | Azure Xt Dr Mri Surescan, Venaseal |
| Medtronic Vascular, INC. | $343.88 | 2019-2020 | |
| Shockwave Medical, INC | $286.31 | 2019-2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Heartflow, INC. | $278.86 | 2023-2025 | Ffrct |
| Amgen INC. | $251.29 | 2019-2025 | Repatha |
| Biotronik INC. | $151.35 | 2023 | Edora 8 Dr-T |
| Getinge USA Sales, LLC | $140.41 | 2025 | Cardiosave Rescue |
| Edwards Lifesciences Corporation | $129.31 | 2024 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Sanofi-Aventis U.S. LLC | $124.58 | 2019 | |
| Novo Nordisk INC | $120.60 | 2023 | |
| Boston Scientific Corporation | $112.59 | 2019-2023 | Accolade Sr |
| Boehringer Ingelheim Pharmaceuticals, INC. | $89.54 | 2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $72.28 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $53.74 | 2020-2023 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cardiva Medical, INC. | $33.06 | 2025 | Cardiva Vascade Mvp Vvcs 6-12f |
| Kiniksa Pharmaceuticals, LTD. | $31.39 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $19.48 | 2025 | Eliquis |
| Octapharma USA, INC. | $18.74 | 2025 | Fibryga |
| Pfizer INC. | $14.03 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rajinder Singh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.